July 16, 2020 Rentschler Biopharma’s expansion plans at U.S. site driven by an innovative business model
Federico Pollano, Senior Vice President of Global Business Development at Rentschler Biopharma, spoke with the European Biotechnology Magazine about the expansion plans at our U.S. site in Milford. He shared how our innovative, client-oriented business model allows for the flexible allocation of resources in the drug substance supply for our clients. The very same model forms the basis of our strategic collaboration with Genmab, for the process development and manufacturing of bispecific antibodies generated with Genmab's DuoBody® technology platform.
This partnership represents a first-of- its-kind collaboration that will involve several novel projects and enable the client to decide in a flexible and agile way, which projects to advance and when. Hence, our clients benefit from the freedom to transfer a broad portfolio of products to Rentschler Biopharma and then flexibly determine the course of their project based on clinical read-outs and management decisions.
Please find the full interview here.
Rentschler Biopharma SE
Dr. Cora Kaiser
Senior Director Corporate Communication